QY301

QY301 is a synthetic peptide drug candidate developed by E-Nitiate Biopharmaceuticals Hangzhou for the treatment of inflammatory bowel diseases, specifically ulcerative colitis and Crohn's disease. The drug is designed to address immune system and digestive system disorders. As of the latest updates, its highest development status is IND (Investigational New Drug) application in both China and the United States. The precise mechanism of action has not been publicly disclosed; some sources list it as "unknown." Preclinical studies have indicated good local absorption characteristics and rapid systemic degradation[1][2][8]. The route of administration has been reported as oral or topical[3].